Prelude Therapeutics Incorporated reported earnings results for the third quarter ended September 30, 2022. For the third quarter, the company reported net loss was USD 29.96 million compared to USD 30.69 million a year ago. Basic loss per share from continuing operations was USD 0.63 compared to USD 0.66 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.12 USD | +3.00% | +8.42% | -3.51% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.51% | 220M | |
+41.79% | 50.93B | |
-0.56% | 42.12B | |
+49.62% | 42.05B | |
-7.20% | 29.18B | |
+12.59% | 26.02B | |
-21.51% | 18.9B | |
+6.92% | 13.21B | |
+24.91% | 12.17B | |
+29.60% | 12.16B |
- Stock Market
- Equities
- PRLD Stock
- News Prelude Therapeutics Incorporated
- Prelude Therapeutics Incorporated Reports Earnings Results for the Third Quarter Ended September 30, 2022